Evercore ISI initiates Lycia stock with outperform rating

Evercore ISI initiated coverage on Lycia Therapeutics (NASDAQ:LYCA) with an outperform rating and a $43 price target, citing its LYTACs technology. The company's lead program targets IgE, with clinical trials for food allergies and Graves disease. Lycia raised $318 million in its IPO, priced at $18 per share. Jefferies and TD Cowen also initiated coverage with buy ratings and price targets of $50 and unspecified, respectively.

Original reporting
Published Nov 17, 2026, 9:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 9:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LYCA
Bullish
medium confidence
Mentioned
$LYCA
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LYCABullishMed
01

Why it matters

The new analyst initiation provides a fresh valuation anchor and highlights near-term scientific checkpoints (PK/PD measures expected next year) that can influence trading around biotech risk appetite.

02

Market read

Traders may adjust LYCA positioning based on the new rating/target, while monitoring the next-year PK/PD readouts and the 2028 Phase 2b start as the next fundamental inflection points.

03

What to watch

The piece also notes the stock may be overvalued versus fair value and that the company is still unprofitable, which can cap follow-through if risk appetite fades.

Relevance 5/10Novelty 5/10Timing: today, as the initiation and target are newly introduced to the market

Background

Lycia Therapeutics is a clinical-stage biotech developing LYTACs, including an IgE degrader for food allergy and a Graves disease program targeting TSH receptor antibodies.

Company-level read

Ticker impact

$LYCABullishMedium confidence
Context

Evercore ISI initiated coverage on Lycia Therapeutics with an Outperform rating and a $43 price target, citing its LYTAC IgE and Graves programs.

Expected impact

Likely upward bias as traders price in the initiation target, tempered by the clinical-stage timeline and unprofitability.

Evidence & confidence

The article provides a fresh, attributable catalyst (new coverage and target) plus specific development milestones (PK/PD next year, Phase 2b start in 2028), which shape risk/reward expectations.

Market effects

Reinforces positive sentiment toward extracellular targeted protein degradation (LYTACs) and immunology-focused biotech platforms.

Limited, primarily affects US small/mid-cap biotech sentiment rather than broad regional flows.

Low; the catalyst is company-specific analyst initiation and does not indicate a global macro or cross-market shock.

Counterpoint

The article’s upside case is valuation-driven and heavily dependent on future clinical milestones, so the initiation may not change fundamentals until PK/PD and Phase 2b progress.

Key entities

  • Lycia Therapeutics

    NASDAQ-listed clinical-stage biotech developing LYTACs for IgE-mediated food allergy and Graves disease.

  • Evercore ISI

    Initiated coverage with an Outperform rating and a $43 price target.

Related articles

$LYCAHighAI 9/10

Lycia Therapeutics raises $365M in upsized Nasdaq IPO

Lycia Therapeutics (LYCA) raised $365.1M in its Nasdaq IPO, selling 20.29M shares at $18 each, including underwriters' options. The biotech firm focuses on therapeutics for autoimmune and allergic diseases, with lead candidates LCA-0061 and LCA-0321. The offering was managed by Jefferies, TD Cowen, Evercore ISI, and Guggenheim Securities, with LifeSci Capital as a passive manager.